BioPartners supports a broad spectrum of oncology research, covering both solid tumors and hematologic malignancies. Our capabilities span IVD/device performance studies, biomarker-driven clinical trials, observational programs, and precision-medicine initiatives that require high-quality, well-characterized biospecimens.

We specialize in collecting and processing samples essential for genomic profiling, immunohistochemistry, next-generation sequencing, ctDNA analysis, and emerging liquid biopsy technologies. Our integrated CRO + clinical site model ensures the highest level of protocol adherence and quality oversight, providing sponsors with detailed clinical annotations and consistent, reproducible datasets.

Our clinical teams are trained to support complex oncology workflows, including multi-timepoint sampling, matched biospecimen procurement, temperature-controlled chain-of-custody management, and real-time documentation. With access to diverse patient populations across California and Eastern Europe, we accelerate oncology enrollment and generate robust datasets that strengthen diagnostic validation efforts and therapeutic development.

BioPartners is committed to advancing personalized oncology by ensuring that every biospecimen, every data point, and every study element reflects scientific rigor and operational excellence.

BioPartners supports clinical research across endocrine and metabolic disorders, including diabetes, thyroid dysfunction, adrenal imbalances, lipid disorders, and obesity-related conditions.

These studies often require long-term follow-up, repeat sampling, and careful tracking of clinical parameters such as glucose levels, hormone profiles, metabolic biomarkers, anthropometric measures, and treatment response.

Our integrated model enables seamless coordination of multi-visit protocols and serial biospecimen collections.

We provide high-quality plasma, serum, urine, saliva, and dried blood spot samples with precise clinical annotation. Our experienced teams ensure proper timing, fasting-state verification (if required), validated sample processing, and temperature-controlled storage.

BioPartners also supports diagnostic development for metabolic biomarkers, endocrinology assays, and device validation for glucose monitoring or hormone testing.

With strong operational discipline and a patient-centered approach, we help sponsors generate reliable evidence for early-phase discovery, late-phase clinical studies, and real-world evidence programs in metabolic and endocrine research.

BioPartners has extensive experience executing infectious disease studies, including diagnostic validation programs, respiratory and non-respiratory multi-swab studies, comparative device performance evaluations, and large-scale biospecimen procurement.

We support studies involving viral, bacterial, and fungal pathogens, offering controlled workflows for swab collection, blood draws, stool samples, saliva, and other specimen types. Our teams adhere to strict biosafety protocols and standardized sample-handling procedures designed to maintain the stability, accuracy, and reliability of sensitive analytes.

Our infectious disease capabilities are strengthened by access to diverse symptomatic and asymptomatic populations, enabling efficient enrollment for studies requiring matched swabs, serial sampling, or seasonally dependent recruitment. We work closely with sponsors developing point-of-care tests, molecular assays, multiplex platforms, and rapid diagnostics.

BioPartners’ infrastructure ensures accurate labeling, temperature-controlled transport, adherence to IATA regulations, and seamless communication throughout the study lifecycle.

Our operational expertise produces high-quality results that support assay validation, regulatory submissions, and large commercial diagnostic launches.

BioPartners supports cardiovascular research involving diagnostic validation, device performance studies, biomarker development, therapeutic evaluations, and observational programs.

We work with sponsors developing assays for cardiac biomarkers (e.g., troponins, BNP/NT-proBNP, D-dimer), vascular inflammation markers, lipid panels, and emerging precision cardiology biomarkers.

Our clinical teams follow standardized measurement procedures to ensure the accuracy and consistency of cardiovascular data. We manage detailed clinical information including symptom history, risk profiles, medical background, imaging results (if provided), and medication use.

Sample types may include plasma, serum, whole blood, urine, and additional specialized matrices as needed. Our controlled workflows ensure high biospecimen integrity and reproducibility — critical for cardiovascular innovation.

BioPartners’ network provides access to diverse patient populations, supporting studies involving acute presentations, chronic cardiovascular conditions, and population-level screening programs.

Quality, consistency, and reliability define our cardiovascular research capabilities.